Efalizumab
Authors: Wellington, Keri1; Perry, Caroline M.1
Source: American Journal of Clinical Dermatology, Volume 6, Number 2, 2005 , pp. 113-118(6)
Publisher: Adis International
Key:
- Free Content
- New Content
- Subscribed Content
- Free Trial Content
- Free Content
- New Content
- Subscribed Content
- Free Trial Content
Abstract:
Efalizumab is a humanized monoclonal antibody that binds to CD11a, the 
-subunit of lymphocyte function-associated antigen-1, and consequently inhibits T-cell activation. In randomized, double-blind, placebo-controlled trials, efalizumab 1.0 mg/kg, administered subcutaneously once weekly for 12 weeks, significantly reduced disease activity in patients with chronic, moderate-to-severe plaque psoriasis. Significantly more efalizumab recipients had a 
75% decrease in the Psoriasis Area and Severity Index (PASI) score [22.4–38.9%] than placebo recipients (2.4–4.9%); an additional 12 weeks of treatment resulted in sustained or increased PASI responses. The efficacy of weekly subcutaneous efalizumab was maintained during 15 months of treatment. Efalizumab significantly improved health-related quality of life in patients with chronic plaque psoriasis, with significant improvements in all the Dermatology Life Quality Index domains. Efalizumab was generally well tolerated in patients with chronic, moderate-to-severe plaque psoriasis, with few serious adverse events or treatment withdrawals. The most common adverse events were headache, chills, myalgia, pain, and fever; these most often occurred within 2 days of administration of the drug, were most frequent after the first or second dose, and decreased in frequency over time.
Keywords: Adis Drug Profiles; Efalizumab, general; Psoriasis, treatment
Document Type: Research article
Affiliations: 1: Adis International Inc., Yardley, Pennsylvania, USA
Key:
- Free Content
- New Content
- Subscribed Content
- Free Trial Content
- Free Content
- New Content
- Subscribed Content
- Free Trial Content
Click here for Page Help